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Abstract Rap1A and Rap1B are small GTPases of the Ras
superfamily whose activation can be measured using a probe that
interacts specifically with the GTP-bound forms of Rap1A and
Rap1B. Using this procedure we demonstrate that the cyclic
AMP-elevating agent forskolin activates both Rap1A and
Rap1B in Rat1 cells. Whilst the protein kinase A inhibitor
H89 ablated the ability of forskolin to cause cAMP response
element binding protein (CREB) phosphorylation in Rat1 cells, it
did not affect the ability of forskolin to activate either Rap1A
and Rap1B. Forskolin differentially activated Rap1A and Rap1B
isoforms in a time- and dose-dependent manner. The cAMP-
specific type 4 family phosphodiesterase inhibitor rolipram
potentiated the rate of activation of both Rap1A and Rap1B
by forskolin challenge of Rat1 cells. Challenge of Rat1 cells with
rolipram alone was able to elicit the phosphorylation of CREB
but not activation of either Rap1A or Rap1B. ß 2000 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Rap1 is a member of the Ras family of small GTPases and
is involved in the control of cell growth and morphogenesis,
although the downstream e¡ectors of Rap1 still remain to be
fully elucidated. [1]. There are two known forms of Rap1,
called Rap1A and Rap1B, that di¡er in their extreme C-ter-
mini [2]. They have been shown to be activated by a wide
variety of ligands, including cAMP, diacylglycerol, Ca2,
bombesin as well as by changes in cell adhesion and cell den-
sity [1,2,17]. When activated, Rap1 switches from a GDP-
bound, inactive state to a GTP-bound, active state. This
switch is controlled by the action of both guanine nucleotide
exchange factors (GEFs) and GTPase-activating proteins [1].
Both Rap1 forms have protein kinase A (PKA) phosphoryla-
tion sites located within their C-terminal region and it was
originally surmised that activation of these GTPases ensued
as a result of their PKA-mediated phosphorylation. However,
it has also been suggested that Rap1 proteins may be acti-
vated by cAMP through a process that does not involve PKA
[3^7]. In this regard, recent attempts to delineate the pathway
by which cAMP activates Rap1 have implicated the direct
activation of these small GTPases by a recently discovered
family of GEFs. Such cAMP-regulated GEFs have been
named as either cAMP-GEFs or as EPACs (exchange protein
directly activated by cAMP). These GTPase exchange proteins
appear to be activated by the direct binding of cAMP and
therefore represent a novel mechanism for governing signal-
ling speci¢city within the cAMP cascade [4,5].
Rap1 activation has normally been followed by a GTP
loading assay [6]. However, a novel activation-speci¢c assay
for Rap1 has recently been developed [8^11,19]. This assay
exploits the ability of the activated, GTP-bound forms of
Rap1 to bind to the Ras binding domain (RBD) of the Ral
form of guanine nucleotide dissociation stimulator protein
(RalGDS) [8^11]. Expression of this domain as a GST fusion
protein thus allows activated GTP-bound Rap1 forms to be
isolated in pull-down assays. The amount of associated Rap1
then provides a direct quanti¢cation of the degree of activa-
tion. As this precipitated material can then be blotted with an
appropriate anti-Rap1 antibody, such a method allows for the
selective discrimination of Rap1A activation compared to that
of Rap1B.
Previous studies using this assay method analysed Rap1
activation using antisera that did not discriminate between
the Rap1A and Rap1B isoforms [8^11]. Here, for the ¢rst
time, we have used isoform-speci¢c antibodies to evaluate
the activation of endogenously expressed Rap1A and Rap1B
isoforms in Rat1 ¢broblasts. We demonstrate that the adenyl-
yl cyclase activator forskolin causes distinct dose-dependent
and time-dependent activation pro¢les for both Rap1 iso-
forms.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM), newborn calf serum
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(NCS), foetal calf serum (FCS), glutamine, penicillin/streptomycin so-
lution, anti-goat IgG and anti-rabbit IgG horseradish peroxidase were
from Sigma. N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesul-
phonamide (H89) was from Calbiochem. 4-{3-(Cyclopentoxyl)-4-me-
thoxyphenyl}-2-pyrrolidone (rolipram) was a gift from Schering. Anti-
mouse IgG horseradish peroxidase antibody and ECL reagents were
from Amersham. Complete protease inhibitor tablets were from
Boehringer Mannheim. Goat, polyclonal antibodies to Rap1A and
Rap1B were from Santa Cruz. Anti-phospho cAMP response element
binding protein (CREB) and anti-CREB protein antibodies were from
New England Biolabs.
2.2. Construction of expression vectors
Wild-type Rap1B-HA was cloned from image clone 504434 using
speci¢c primers to the published Rap1B sequence: (sense oligo:
TGCAGGAATT CACCATGCGT GAGTATAAGC TAGT and
antisense oligo: CTGATCTCGA GTTAAGCGTA ATCTGGAACA
TCGTATGGGT AAAGCAGCTG ACATGATG). The 3P oligonu-
cleotide encodes a HA epitope sequence in-frame with the terminal
amino acid of the Rap1B coding region. RapV12 was constructed
following PCR ampli¢cation of the full-length Rap1B-HA clone, us-
ing a mutant 5P oligonucleotide primer (sense oligo: TGCAGGAATT
CACCATGCGT GAGTATAAGC TAGTCGTTCT TGGCTCA-
GTA GGCGTT) resulting in a valine for glycine substitution at ami-
no acid 12. RapN17 was constructed following PCR ampli¢cation of
the full-length clone, using a mutant sense oligonucleotide primer:
TGCAGGAATT CACCATGCGT GAGTATAAGC TAGTCG-
TTCT TGGCTCAGGA GGCGTTGGAA AGAATGCTTT GAC-
TGTA. The resultant ampli¢cation products were subcloned into
the EcoRI and XhoI sites of the mammalian expression vector pc-
DNA3 (Invitrogen) and then sequenced.
The Rap binding domain of RalGDS (RalGDS-RBD) was cloned
by reverse transcriptase PCR. The template cDNA was synthesised
from 1 Wg of human embryonic kidney HEK293 cell RNA using
primer ATGCCCTTGG CAATCTTGAG. Approximately 1/20th of
the reverse transcribed product was used to prime a 30-cycle PCR
reaction using sense, ATCTGAATTC GCGCTGCCGC TCTACA-
ACCA, and antisense, GTACAGTCGA CTCAGGTCCG CTTCT-
TGAGG ACAA, primers. The ampli¢cation product was subcloned
into the EcoRI and SalI sites of pGEX6X. The ¢delity of the
RalGDS-RBP construct was con¢rmed by automated sequencing.
2.3. Cell culture
The COS1 monkey kidney cell line and Rat1 ¢broblasts were main-
tained at 37‡C in an atmosphere of 5% CO2, 95% air in complete
growth medium containing DMEM supplemented with 0.1% penicil-
lin/streptomycin (10 000 U/ml) and 10% FCS. Details have been de-
scribed previously [12,13]. For transfection, growth medium was re-
placed with 5 ml of DMEM containing 10% (v/v) NCS and 0.1 mM
chloroquine. Plasmid DNA (10 Wg) was diluted to 250 Wl with TE
bu¡er [10 mM Tris^HCl (pH 8.0)/1 mM EDTA] mixed with 200 Wl of
DEAE-Dextran (10 mg/ml) and incubated for 10 min at room temper-
ature. The DNA solution was added to cells and incubated for 4 h at
37‡C. The transfection medium was aspirated and the cells were
shocked with 10% (v/v) dimethyl sulphoxide in phosphate-bu¡ered
saline (PBS) for 2 min at room temperature. The monolayer was
then washed twice with 5 ml of PBS and then incubated for 48 h in
DMEM containing 10% (v/v) FCS. Before use COS1 and Rat1 cells
were incubated in serum-free medium for 16 h.
2.4. Expression and puri¢cation of RalGDS as a GST fusion protein
An overnight culture of JM109 bacteria bearing the vector
pGEX6X-RalGDS-RBP was diluted 1:10 (v/v) in LB (10 g/l (w/v)
tryptone, 10 g/l (w/v) NaCl, 5 g/l (w/v) yeast extract) containing 50
Wg/ml ampicillin and grown for a further hour at 37‡C. Protein syn-
thesis was induced for 4 h with the addition of 1 mM IPTG. Cells
were then pelleted (4000Ug, 10 min, 4‡C) and frozen at 380‡C over-
night to break bacterial cell walls. The following day cells were resus-
pended in 10 ml of 50 mM Tris^HCl, pH 8.0, 100 mM NaCl, 1 mM
EDTA, 10 mM L-mercaptoethanol containing protease inhibitor
cocktail. Cell suspensions were sonicated on ice to shear DNA
(4U30 s bursts), after which 0.02% Triton X-100 was added and
then cell debris was pelleted by centrifugation (13 000Ug, 10 min,
4‡C). The supernatant was transferred to a 10 ml centrifuge tube
and incubated for 30 min on a rotary shaker at 4‡C with 1 ml of
pre-equilibrated glutathione Sepharose beads (Pharmacia). Beads were
recovered by centrifugation at 2000Ug for 1 min, washed in resus-
pension bu¡er containing 0.02% (v/v) Triton X-100 and fusion protein
eluted in 2.4 ml of 5 mM glutathione, 50 mM Tris, pH 8.0. To remove
glutathione eluates were dialysed, with three changes against 50 mM
Tris^HCl, pH 8.0, 100 mM NaCl, 5% (v/v) glycerol and stored at
380‡C until use.
2.5. Rap1 activation assay and immunoblotting
GST-RalGDS-RBD was used to determine the relative amount of
active GTP-bound Rap1 as previously described [11]. Detergent ex-
tracts of whole cells were prepared by solubilisation in 55 mM Tris^
HCl, pH 7.4, 132 mM NaCl, 22 mM NaF, 11 mM sodium pyrophos-
phate, 10 mM magnesium chloride, 1% Nonidet P40 containing com-
plete protease inhibitor cocktail (Boehringer). Cell extracts were in-
cubated with 10 Wg of immobilised GST-RalGDS-RBD for 60 min at
4‡C. The beads were then washed four times in lysis bu¡er, followed
by SDS^PAGE and immunoblotting with anti-HA antiserum, anti-
Rap1A or anti-Rap1B antibodies all used at a concentration of 1:500
(v/v). CREB activation in cell lysates was detected with phospho-
CREB antibodies as described [14].
3. Results and discussion
3.1. Evaluating the RalGDS binding assay for assessing Rap1
activation
Recently it has been suggested that RalGDS-RBD, when
expressed as a GST fusion protein in Escherichia coli, can be
used to isolate speci¢cally GTP-bound Rap1 forms and thus
serve as a speci¢c probe to determine Rap1 activation [11].
We set out to evaluate independently the ¢delity of this novel
system. To do this we ¢rst expressed RalGDS-RBD as a GST
fusion protein in E. coli and puri¢ed it on glutathione agarose
(Fig. 1a). We then transiently transfected COS1 cells with a
wild-type form of Rap1B. To ensure that we were able to
monitor its activation independently of any endogenous
Rap1 proteins expressed in COS cells we generated a HA
epitope-tagged form of Rap1 and detected it with an antibody
that was speci¢c for this tag. We then treated these cells with
the diterpene forskolin (1 WM), which is known to activate
adenylyl cyclase in these cells and to elevate cAMP levels
[15,16]. The transfected COS cells were then lysed and the
GTP-bound form of Rap1B was isolated with the GST fusion
protein of RalGDS-RBP with detection done by immunoblot-
ting with a HA-speci¢c monoclonal antibody in order to de-
tect the bound, epitope-tagged Rap1B.
This clearly showed that forskolin treatment of transfected
COS cells led to a robust activation of transiently transfected
HA epitope-tagged Rap1B (Fig. 1a,b). In order to provide a
control to evaluate the authenticity of this assay we generated
the N17 mutant form of Rap1B in order to provide a domi-
nant negative form that should not interact with RalGDS-
RBP [1], again this was HA epitope-tagged so that we could
detect it speci¢cally. This demonstrated that the N17-Rap1B
form failed to bind in forskolin-challenged cells (Fig. 1b,c). In
order to gauge the maximal level of interaction in this assay
and to provide and independent positive control, we generated
the constitutively activated V12-Rap1B mutant form, again as
a HA epitope-tagged form. The V12 mutation inactivates the
Rap1 GTPase and thus allows Rap1 to accrue in a fully GTP-
bound form in cells [1,2]. Consistent with this, we were able to
show (Fig. 1b,c) that this form of Rap1B was able to associate
with RalGDS-RBP in cells that had not been challenged with
forskolin. Indeed, the degree of association was similar to that
seen for wild-type Rap1B subsequent to forskolin challenge
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(Fig. 1c). This implies that such forskolin treatment of COS
cells su⁄ced to maximally activate the transfected Rap1B.
Consistent with this, we noted that forskolin failed to increase
the amount of constitutively activated V12-Rap1B associated
with RalGDS-RBP in transfected COS cells (Fig. 1).
These results demonstrate that the RalGDS-RBP probe can
be used to identify active Rap1 generated by forskolin treat-
ment of wild-type Rap1.
3.2. Forskolin and 8-bromo-cAMP activation of endogenous
Rap1 isoforms in Rat1 ¢broblasts
We set out to examine whether forskolin might lead to the
activation of endogenously expressed Rap1A and Rap1B iso-
forms. To do this we employed antisera that were capable of
discriminating between Rap1A and Rap1B isoforms (Fig. 2a).
We chose to evaluate Rat1 ¢broblasts, as we were able to
show, immunologically, that these cells expressed the 21
kDa forms of both Rap1A and Rap1B (Fig. 2b).
In order to determine whether increased levels of cAMP
activated these forms, we treated Rat1 cells with forskolin
(1 WM) and isolated the GTP-bound forms of activated
Rap1 in pull-down assays with RalGDS-RBD. The active
forms of both Rap1A and Rap1B were then separately de-
tected with isotype-speci¢c antisera able to recognise the
unique C-termini of Rap1A and Rap1B. Challenge with for-
skolin increased the level of Rap1A and Rap1B immunoreac-
tivity associated with RalGDS-RBD, indicative of Rap1 acti-
vation in these treated cells (Fig. 2b).
Forskolin-induced activation of Rap1A and Rap1B was
completely una¡ected by the PKA inhibitor H89 (Fig. 2b),
indicating that such activation was independent of PKA acti-
vation in these cells [22]. However, we wished to ascertain
whether H89 did, indeed, serve as an e¡ective inhibitor of
PKA action in these cells under the conditions utilised here.
To do this we showed that challenge of Rat1 cells with the
adenylyl cyclase activator forskolin, increased the phosphory-
lation of the transcription factor CREB (Fig. 2c). PKA acti-
vation, as a consequence of increased cAMP levels, has been
shown to phosphorylate this protein at a single site, Ser-133
[23]. Consistent with this, H89 served to totally ablate this
action of forskolin on CREB phosphorylation (Fig. 2c). It
would thus appear that the Rap1 forms in Rat1 cells are
activated by forskolin in a PKA-independent fashion.
To evaluate whether increased cAMP levels did indeed ac-
tivate these Rap1 isoforms we also challenged the Rat1 cells
with the cell-permeable cAMP analogue, 8-bromo-cAMP
(10 WM). This too was capable of activating both Rap1A
and Rap1B isoforms and, as with forskolin, this process was
una¡ected by the PKA inhibitor H89 (Fig. 2d).
We then set out to determine the dose dependence of acti-
vation of these Rap1 forms by forskolin. This, intriguingly,
demonstrated that forskolin appeared to activate Rap1B at
lower concentrations than caused Rap1A activation (Fig.
3a). Thus the EC50 value for forskolin activation of Rap1A
was 0.2 þ 0.1 WM and for Rap1B was strikingly di¡erent at
0.01 þ 0.05 WM (mean þ S.D.; n = 3 separate experiments). A
similar di¡erential e¡ect was observed when we employed
8-bromo-cAMP, with the EC50 values for activation of
Rap1A being 0.12 þ 0.01 WM and for Rap1B at 0.011 þ
0.003 WM (mean þ S.D.; n = 3 separate experiments). There
are many possible explanations for such di¡erences. For ex-
ample, it could be that either di¡erent EPACs/cAMP-GEFs
control the activation of these two Rap1 forms and that these
have di¡erent a⁄nities for activation by cAMP or that di¡er-
ent levels of occupancy of the EPAC/cAMP-GEF by cAMP
are needed to elicit Rap1A and Rap1B activation. However,
insight into this apparent di¡erence can be gleaned from ob-
servations concerning the rate of activation of these two Rap1
Fig. 1. Activation of Rap1B in transiently transfected COS1 cells. a: Coomassie blue protein stain of an SDS gel analysing a lysate from E. coli
cells that had either been treated (induced) or not (uninduced) with IPTG to induce expression of RalGDS-GST fusion protein (major staining
band in induced track). Also shown is a track for the speci¢c eluate from a glutathione a⁄nity column, showing the puri¢cation of RalGDS-
GST. b: Con£uent COS1 cells (Mock) and COS1 cells transfected with cDNAs encoding HA epitope-tagged versions of wild-type (Rap1B-
HA), constitutively active (V12-Rap1B-HA) and dominant negative (N17-Rap1B-HA) forms of Rap1B were challenged with 1 WM forskolin
for 10 min. Cells were then lysed and active, GTP-bound forms of Rap1 were isolated with RalGDS (see Section 2). The bound, and hence ac-
tive, forms of Rap1 were speci¢cally detected by immunoblotting with anti-HA antibody. c: The data from three experiments of the form de-
scribed in b were analysed densitometrically. Maximal activation (100%) was taken for that described by the V12-Rap1B form (means þ S.D.;
n = 3).
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isoforms in forskolin-challenged Rat1 cells. Thus, in the pres-
ence of maximally e¡ective dose of forskolin (10 WM), activa-
tion of Rap1B preceded that of Rap1A (Fig. 3b,c). Thus the
apparent diminished sensitivity of Rap1A to activation by
forskolin may re£ect the fact that in using a single time point
to determine activation we may have underestimated Rap1A
activation, relative to Rap1B activation, especially at the low-
er doses of forskolin.
It is then very intriguing that the activation of the Rap1A
isoform is slow compared to activation of Rap1B. We then set
out to evaluate if inhibiting cAMP degradation could aug-
ment the rate of Rap1 activation by forskolin. It is well estab-
lished that inhibition of cAMP phosphodiesterase (PDE) ac-
tivity can potentiate the ability of adenylyl cyclase activators,
such as forskolin, to elevate intracellular cAMP levels [18]. At
least six di¡erent gene families encode PDE enzymes able to
hydrolyse cyclic AMP [15]. However, the activity of members
of the type 4 family of PDE (PDE4) provides the major PDE
activity in Rat1 cells (M.D. Houslay, E. Huston, C. Shepherd,
unpublished). These enzymes can be selectively inhibited with
the anti-in£ammatory and anti-depressant compound roli-
pram [18]. The addition of rolipram to Rat1 cells, at a con-
centration (10 WM) known to cause maximal inhibition of this
family of phosphodiesterases [18], potentiated the rate of ac-
tivation of both Rap1A and Rap1B by forskolin but did not
increase the maximal level of activation (Fig. 3b,c). Thus the
presence of rolipram served to emphasise the di¡erent rates of
activation of these Rap1 isoforms, with forskolin and roli-
pram together activating Rap1B within 2 min, whilst Rap1A
activation only began to be evident at around 10 min. This
e¡ect of rolipram was una¡ected by the PKA inhibitor H89
(data not shown), indicating that rolipram exerted its action
of these Rap1 forms in a fashion that was independent of
PKA activation.
The addition of rolipram (10 WM) alone to Rat1 cells for 20
min led to CREB phosphorylation (Fig. 2c) up to levels com-
parable to that achieved using forskolin (10 WM; data not
shown). In contrast to this, treatment of Rat1 cells with roli-
pram (10 WM; 20^40 min) did not lead to the activation of
either Rap1A or Rap1B (data not shown). This indicates a
functional compartmentalisation of cAMP signalling in these
cells.
Fig. 2. Activation of Rap1 isoforms in Rat1 cells. a: COS1 cells were transfected to express HA epitope-tagged forms of either Rap1A or
Rap1B. Then lysates from either untransfected cells (track 1), Rap1A-transfected (track 2) or Rap1B-transfected cells (track 3) were immuno-
puri¢ed with the HA-speci¢c monoclonal antibody and Western blotted with either the Rap1A-speci¢c antiserum (upper panel) or the Rap1B-
speci¢c antiserum (lower panel). The Rap1A-speci¢c antiserum identi¢ed a single 21 kDa immunoreactive species only in the Rap1A-transfected
cells and vice versa for the Rap1B-speci¢c antiserum. b: Rat1 cells were grown to con£uence, and stimulated with, as indicated, 10 WM forsko-
lin, 10 WM H89 or a combination of the two agents for 20 min. Cells were lysed and GTP-bound forms of Rap1 were isolated using the Ral-
GDS pull-down assay and detected with speci¢c antisera to Rap1A and Rap1B as described in Section 2 (¢rst and third panels). In addition,
equal amounts of cell extract (10 Wg) were subjected to SDS^PAGE and immunoblotted with antisera to Rap1A and Rap1B (second and
fourth panels). c: Rat1 cells were treated as above except, where indicated, the PDE4-selective inhibitor rolipram was added (10 WM). Lysates
were then treated with antibodies that recognise the phosphorylated form of CREB (upper band indicated with arrow). In addition, lysates
were blotted using an antibody that detects both phosphorylated and unphosphorylated forms of CREB (lower panel) in order to gauge that
equal loading was done. Results are representative of an experiment carried out on three separate occasions. d: Rat1 cells were treated with
8-bromo-cAMP (20 WM) þ H89 (10 WM), as above, with Ral-GDS pull-down and blotting analyses done, as above, for Rap1A and Rap1B acti-
vation. In addition, blotting was done, as above, to gauge CREB phosphorylation and total CREB levels. These blots are typical of experi-
ments done at least three times.
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4. Conclusions
Using an independent assessment system, we show here that
binding to RalGDS-RBP provides an e¡ective means of de-
termining Rap1 activation in intact cells. We then have ex-
tended this to show that it can be used to make independent
assessments of the separate activation of Rap1A and Rap1B
isoforms in Rat1 cells. This could be triggered in a PKA-
independent fashion using either forskolin to activate adenylyl
cyclase or using the cell-permeable cAMP analogue, 8-bromo-
cAMP. This is consistent with the notion that Rap1 proteins
can be converted to their GTP-bound forms and thus acti-
vated through the action of EPACs/cAMP-GEFs as recently
suggested [4,5].
Our ability to discriminate between the activation of Rap1A
and Rap1B, however, indicated that forskolin caused the ac-
tivation of Rap1B at a faster rate than it caused the activation
of Rap1A. In each case, the rate of activation was augmented
by the presence of the PDE4 cAMP phosphodiesterase inhib-
itor rolipram. This can be expected to potentiate the level of
cAMP accumulation sustained by forskolin activation of ad-
enylyl cyclase and hence the degree of occupancy of EPACs/
cAMP-GEFs. The di¡erences in rates of activation of these
two Rap1 isoforms could re£ect their coupling to EPACs/
cAMP-GEFs with di¡erent a⁄nities for cAMP or di¡erences
in a⁄nity of the Rap1 isoforms for cAMP-bound EPACs/
cAMP-GEFs. This functional compartmentalisation of
cAMP signalling in Rat1 cells also appears to extend to the
e¡ect of PDE4 enzyme inhibition of the Rap1 enzymes com-
pared to CREB activation. For inhibition of PDE4 enzymes
by rolipram appears to su⁄ce in itself to elicit CREB phos-
phorylation whilst adenylyl cyclase activation is needed to
elicit Rap1 activation whereupon PDE4 inhibition can then
serve to augment it.
Whatever provides the underlying molecular mechanism,
our study emphasises the need not only to evaluate separate-
ly Rap1A and Rap1B activation but also to take particular
note of temporal di¡erences in activation rates that may oc-
cur. Failure to do this may lead to erroneous conclusions
concerning the regulation of these two species. In any event,
it would seem that we have made the novel observation
that these two Rap1 isoforms can be di¡erentially regulated
by changes in cAMP levels. In that way the Rap1 system
is analogous to the PKA system, where the binding of
RII-PKA isoforms to anchor proteins allows for the selec-
tive regulation of PKA sub-populations through their re-
sponses to intracellular gradients of cAMP compartmentalised
[15,20,21].
Fig. 3. Dose-dependent activation of Rap1A and Rap1B isoforms by forskolin in RAT1 cells. Serum-starved Rat1 cells were treated, as above,
in order to gauge Rap1 activation by association of the GTP-bound forms of Rap1A and Rap1B with RalGDS-RBP-GST in pull-down assays
with visualisation using isoform-speci¢c antibodies. a: Experiments done with a range of forskolin concentrations for Rap1A and Rap1B.
b: Experiments done over the indicated times with 10 WM forskolin þ 10 WM rolipram for Rap1A. c: Experiments done over the indicated times
with 10 WM forskolin þ 10 WM rolipram for Rap1B. Quanti¢cation was done by densitometric analysis under conditions where linear responses
were determined. Results are means þ S.D. of n = 3 experiments.
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